Volume | 1,193,795 |
|
|||||
News | - | ||||||
Day High | 82.08 | Low High |
|||||
Day Low | 80.97 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Alcon Inc | ALC | NYSE | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
81.13 | 80.97 | 82.08 | 82.01 | 81.46 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
15,569 | 1,193,795 | $ 81.49 | $ 97,284,538 | - | 69.44 - 88.2312 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:00 | 43,124 | $ 82.01 | USD |
Alcon (ALC) Options Flow Summary
Alcon Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
27.06B | 499.70M | - | 9.46B | 974M | 1.95 | 27.78 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Alcon News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 79.58 | 82.08 | 79.36 | 80.61 | 698,366 | 2.43 | 3.05% |
1 Month | 82.00 | 82.47 | 77.54 | 79.72 | 780,602 | 0.01 | 0.01% |
3 Months | 77.52 | 88.2312 | 77.20 | 82.74 | 896,115 | 4.49 | 5.79% |
6 Months | 72.33 | 88.2312 | 69.53 | 78.75 | 884,062 | 9.68 | 13.38% |
1 Year | 78.76 | 88.2312 | 69.44 | 79.01 | 813,483 | 3.25 | 4.13% |
3 Years | 68.85 | 88.78 | 55.21 | 74.32 | 856,288 | 13.16 | 19.11% |
5 Years | 61.04 | 88.78 | 39.37 | 67.55 | 967,503 | 20.97 | 34.35% |
Alcon Description
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun-off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan. |